SOURCE: Market Foundations Inc.

February 06, 2012 09:00 ET

Perception, Opportunity in Volatility - Research & Analysis on Zynga Inc and Gilead Sciences, Inc.

HONG KONG--(Marketwire - Feb 6, 2012) - This morning, www.MarketFoundations.com announced new reports highlighting Zynga Inc (NASDAQ: ZNGA) and Gilead Sciences, Inc. (NASDAQ: GILD). Free research downloads are available at www.MarketFoundations.com/index.php?coa=ZNGA&cob=GILD.

Economic fundamentals leading into 2012 have set a generally positive pace with GDP growth likely to pick up through the coming year. However, there are several important caveats to note as the world economy continues to face headwinds and risks weigh to the downside. Positive outlooks are conditional on fiscal policy in payroll taxes and unemployment insurance benefits and upon the easing of the European debt situation. A repeat of volatility experienced in 2011 is likely in 2012, as perceptions about the strength of the U.S. economy and the euro zone will vary over time as events unfold.

Despite the current situation, our team continues to identify high momentum situations with growth potential -- there remains strong opportunity within careful discretion.

Market Foundations is releasing new coverage on Zynga Inc for its current position within the technology industry. Zynga Inc. (Zynga), formerly Presidio Media LLC, is a social game developer with 232 million average monthly active users (MAUs) in 166 countries. The Company's games are accessible on Facebook, other social networks and mobile platforms to players globally, wherever and whenever they want. It operates its games as live services. The full research report on Zynga Inc (NASDAQ: ZNGA) is available here: www.MarketFoundations.com/index.php?coa=ZNGA.

Market Foundations has released research on Gilead Sciences, Inc. for its changing role within the healthcare industry. Gilead Sciences, Inc. (Gilead) is a biopharmaceutical company. The Company focuses on the development and commercialization of human therapeutics for life threatening diseases. The Company has operations in North America, Europe and Asia Pacific. The Company's products include Truvada, Atripla, Viread, Emtriva, Hepsera, AmBisome, Letairis, Ranexa, Vistide and Cayston. The full research report on Gilead Sciences, Inc. (NASDAQ: GILD) is available here: www.MarketFoundations.com/index.php?cob=GILD.

About Market Foundations
By providing members with financial information services, we provide the foundation investors need to build investing intelligence. The difference between consistently making good investments or bad investments is nothing more than the right information at the right time.

Contact Information